 Crispr Therapeutics is perhaps the most speculative name Im currently buying, though in small sizes, with an expectation to dont look, dont sell for at least 10 years. Analysts expect this company to lose money for the next three years, but with a chance of earning 25-50 of its current stock price every year from 2029-2031. 